Durvalumab plus tremelimumab for advanced hepatocellular carcinoma is associated with a neutrophil/lymphocyte ratio

被引：0
|
作者：
Sugimoto, Rie [1 ]
Senjyuu, Takeshi [2 ]
Aratake, Yoshifusa [3 ]
Kuwano, Akifumi [4 ]
Ueda, Akihiro [5 ]
Nakamura, Tsukasa [6 ]
Goya, Takeshi [7 ]
Morita, Yuusuke [1 ]
Tanaka, Yuki [1 ]
Kojima, Motoyuki [3 ]
Tanaka, Masatake [7 ]
机构：
[1] NHO Kyushu Canc Ctr, Dept Hepatobiliary Pancreatol, Fukuoka, Japan
[2] Kyushu Rosai Hosp, Kitakyushu, Fukuoka, Japan
[3] NHO Kyusyu Med Ctr, Fukuoka, Japan
[4] Iizuka Hosp, Iizuka, Fukuoka, Japan
[5] Saiseikai Fukuoka Gen Hosp, Fukuoka, Japan
[6] Fukuoka City Hosp, Fukuoka, Japan
[7] Kyushu Univ, Dept Med & Bioregulatory Sience, Fukuoka, Japan
来源：
CANCER SCIENCE | 2025年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2184
引用
收藏
页码：963 / 963
页数：1
相关论文
共 50 条
  • [1] Neutrophil-to-lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis
    Suzuki, Takanori
    Matsuura, Kentaro
    Sobue, Satoshi
    Kato, Daisuke
    Hayashi, Katsumi
    Kondo, Hiromu
    Anbe, Kaiki
    Mizoshita, Tsutomu
    Okayama, Kohei
    Okumura, Fumihiro
    Kimura, Yoshihide
    Ozasa, Atsushi
    Inada, Hiroki
    Tokunaga, Takayuki
    Narahara, Satoshi
    Kawamura, Hayato
    Fujiwara, Kei
    Nojiri, Shunsuke
    Kataoka, Hiromi
    Tanaka, Yasuhito
    HEPATOLOGY RESEARCH, 2025,
  • [2] Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
    Kudo, Masatoshi
    HEPATOBILIARY SURGERY AND NUTRITION, 2022, 11 (04) : 592 - 596
  • [3] Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma
    de Castria, Tiago Biachi
    Khalil, Danny N.
    Harding, James J.
    O'Reilly, Eileen M.
    Abou-Alfa, Ghassan K.
    FUTURE ONCOLOGY, 2022, 18 (33) : 3769 - 3782
  • [4] COST-EFFECTIVENESS OF TREMELIMUMAB OR TREMELIMUMAB IN COMBINATION WITH DURVALUMAB VS DURVALUMAB AS TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA
    Tang, T.
    Shi, L.
    VALUE IN HEALTH, 2023, 26 (06) : S138 - S138
  • [5] Cost Effectiveness of Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma in the USA
    Xiong, Xiaomo
    Guo, Jeff Jianfei
    PHARMACOECONOMICS, 2025, 43 (03) : 271 - 282
  • [6] Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2022, 11 (02) : 87 - 93
  • [7] Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma
    Yonemoto, Takuya
    Ogasawara, Sadahisa
    Kanogawa, Naoya
    Miwa, Chihiro
    Fujiya, Makoto
    Tsuchiya, Takahiro
    Sawada, Midori
    Akatsuka, Teppei
    Izai, Ryo
    Yumita, Sae
    Nakagawa, Miyuki
    Okubo, Tomomi
    Koroki, Keisuke
    Inoue, Masanori
    Nakamura, Masato
    Kondo, Takayuki
    Nakamoto, Shingo
    Itokawa, Norio
    Atsukawa, Masanori
    Itobayashi, Ei
    Moriguchi, Michihisa
    Kato, Naoya
    HEPATOLOGY RESEARCH, 2025,
  • [8] Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma
    Tamaki, Nobuharu
    Mori, Nami
    Takaki, Shintaro
    Tsuji, Keiji
    Tada, Toshifumi
    Nakamura, Shinichiro
    Ochi, Hironori
    Mashiba, Toshie
    Doisaki, Masao
    Marusawa, Hiroyuki
    Kobashi, Haruhiko
    Fujii, Hideki
    Ogawa, Chikara
    Nonogi, Michiko
    Arai, Hirotaka
    Uchida, Yasushi
    Urawa, Naohito
    Narita, Ryoichi
    Akahane, Takehiro
    Kondo, Masahiko
    Yasui, Yutaka
    Tsuchiya, Kaoru
    Izumi, Namiki
    Kurosaki, Masayuki
    ANTICANCER RESEARCH, 2024, 44 (09) : 3913 - 3918
  • [9] Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?
    Hatanaka, Takeshi
    Naganuma, Atsushi
    Yata, Yutaka
    Kakizaki, Satoru
    HEPATOBILIARY SURGERY AND NUTRITION, 2022,
  • [10] Postoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio predicts the outcomes of hepatocellular carcinoma
    Li, Chuan
    Wen, Tian-Fu
    Yan, Lu-Nan
    Li, Bo
    Wang, Wen-Tao
    Yang, Jia-Yin
    Xu, Ming-Qing
    JOURNAL OF SURGICAL RESEARCH, 2015, 198 (01) : 73 - 79
12345